StockWatch
·

Lyell Immunopharma, Inc. Q3 FY26 Results

LYELQ3 FY26 Results
Filing
MetricValue ($ M)Q2 FY26Q3 FY25
Revenue0.00100.0%
Total Income0.00100.0%
Expenditure48.302.0%29.6%
PBT—
Net Profit-45.531.7%17.2%
OPM—
NPM—
EPS-1.863.1%12.7%
View full financials

Lyell Immunopharma Reports Q3 2026 Business Highlights and Financial Results

05 Nov 2026 · 5 Nov, 2:53 am

Summary

Lyell Immunopharma reported financial results and business highlights for the third quarter ended September 30, 2026. The company announced updated clinical data for its ronde-cel therapy, with strong response rates observed in the PiNACLE pivotal trial. Significant progress was made in manufacturing technology transfer for LYL273. A private placement financing of $80.0 million was completed, and the company expects its cash reserves to fund operations into 2028. The reported net loss for the quarter was $45.5 million, an increase from $38.8 million in the prior year period, primarily due to increased R&D expenses.

Key Highlights

  1. 1

    Lyell Immunopharma announced updated clinical data from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2 trial 2L cohort of ronde-cel, showing an overall response rate of 91% and a complete response rate of 77% among 44 efficacy-evaluable patients in the 3L+ PiNACLE trial.

  2. 2

    The company reported that PiNACLE pivotal data disclosure is on track for mid-2027, with BLA submission expected to follow in the second half of 2027.

  3. 3

    Lyell Immunopharma completed the technology transfer of LYL273 to the LyFE Manufacturing Center™ following FDA review of an improved manufacturing process and updated analytical methods.

  4. 4

    A private placement financing of $80.0 million was announced with participation from existing and new investors.

  5. 5

    Approximately $194.0 million in cash, cash equivalents and marketable securities as of September 30, 2026, together with net proceeds from the private placement, are expected to fund operations into 2028.

  6. 6

    The company reported a net loss of $45.5 million for the third quarter ended September 30, 2026, compared to a net loss of $38.8 million for the same period in 2025.

Management Comments

L

Lynn Seely

The updated ronde-cel data accepted for presentation at ASH further strengthen our conviction in ronde-cel’s potential to meaningfully improve outcomes for patients with large B-cell lymphoma. The high rates of very durable complete responses achieved by ronde-cel in both the second- and third- or later-line settings, including in patients with high-risk primary refractory disease, clearly showcase the next-generation potential of ronde-cel. With two pivotal trials underway, including our single-arm pivotal PiNACLE trial expected to complete enrollment by year end and on track for pivotal data and BLA submission in the second half of 2027, we are now focusing on preparation for commercialization. We are also continuing to advance LYL273 following the successful transfer of manufacturing to LyFE, as we work to determine the recommended Phase 2 dose and optimize the safety management plan ahead of our planned End-of-Phase 1 discussions with the FDA in 2027.

Informational and educational content only. Not investment advice.